Trials / Completed
CompletedNCT04184232
Treatment of Recurrent Bladder Cancer With Dendritic Cells
Treatment of Recurrent Bladder Cancer With Autologous Monocyte-derived Dendritic Cells
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus · Other Government
- Sex
- Male
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Treatment of recurrent bladder cancer with dendritic cells
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dendritic cells | Autologous dendritic cells primed with muc-1/wt-1 peptides |
| OTHER | Standard treatment according to the Clinical protocols | Standard treatment of bladder cancer according to the Clinical protocols |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2019-12-03
- Last updated
- 2021-01-22
Locations
1 site across 1 country: Belarus
Source: ClinicalTrials.gov record NCT04184232. Inclusion in this directory is not an endorsement.